Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Abbvie Limited .
Filed returns
59
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Abbvie Limited | Taxation | Engagement with Government regarding the business environment in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Abbvie Limited | Health | Framework Agreement on the Pricing and Supply of medicines (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Abbvie Limited | Economic Development and Industry | Competitiveness of Europe and Ireland in relation to Life sciences (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Abbvie Limited | Economic Development and Industry | Competitiveness of Europe and Ireland in relation to Life sciences (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2026 | Abbvie Limited | Health | Competitiveness of Europe and Ireland in relation to Life sciences (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Abbvie Limited | Health | Competitiveness of Europe and Ireland in relation to Life sciences (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Abbvie Limited | Health | A letter to the Minister for Health regarding the EU General Pharmaceutical Legislation (GPL) (Legislation) | 1 | On lobbying.ie |
| May–Aug 2025 | Abbvie Limited | Environment | Urban Waste water treatment Directive (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Abbvie Limited | Economic Development and Industry | Competitiveness of Europe and Ireland in relation to Life sciences (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2024 | Abbvie Limited | Energy and Natural Resources | Discussion with the Minister of state on quality of energy supply in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Abbvie Limited | Health | Meeting with officials from the Department of Health as part of a delegation from the US Chamber of Commerce, to discuss industry wide concerns in Ireland regarding the EU Commission’s proposals to revise the general… (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Abbvie Limited | Health | EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Abbvie Limited | Health | EU Pharmaceutical Strategy and Access to Medicines (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Abbvie Limited | Health | Access to Medicines (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2023 | Abbvie Limited | Health | EU Pharmaceutical Strategy and Access to Medicines (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2023 | Abbvie Limited | EU Affairs | EU Pharmaceutical Strategy (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Abbvie Limited | Health | Dermatology waiting lists (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Abbvie Limited | Health | The need to speed up access to innovative medicines in Ireland, particularly in areas with high unmet need (Legislation) | 9 | On lobbying.ie |
| Sep–Dec 2021 | Abbvie Limited | Health | Access to medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Abbvie Limited | Health | CSR activities - (corporate social responsibilities) (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2021 | Abbvie Limited | Health | Access and reimbursement to medicines (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2021 | Abbvie Limited | Health | Health Policy Engagement - Plant Closure (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Abbvie Limited | Health | Health Policy engagements (Public policy or programme) | 11 | On lobbying.ie |
| May–Aug 2020 | Abbvie Limited | Health | World Hepatitis Day 2020 (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2020 | Abbvie Limited | Health | Discussion about access to medicines (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2020 | Abbvie Limited | Health | Access to medicines and the European Intellectual Property (IP) protection environment (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Invitation to attend AbbVie presentation (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Presentation during IBEC regional meeting (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Neurology policy in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Access to medicines and the European Intellectual Property (IP) protection environment (Public policy or programme) | 11 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | To invite representatives to attend AbbVie STEM events (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | To discuss HCV elimination (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Discussion on Budget 2019 (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Briefing note on access to medicines (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2019 | Abbvie Limited | Health | Meetings to discuss access to medicines (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | Parkinsons Disease funding in Ireland and medicines reimbursement (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | To discuss access to medicines and the European Intellectual Property protection environment (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | To invite Minister to STEM launch event (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | To discuss access to medicines and pharmacy-led substitution (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | To invite representatives to attend AbbVie corporate responsibility event (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | To discuss HCV elimination (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2019 | Abbvie Limited | Health | To discuss access to oncology medicines, HCV elimination and non-medical switching (Public policy or programme) | 10 | On lobbying.ie |
| Jan–Apr 2019 | Abbvie Limited | Health | To invite Minister to STEM event launch (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2019 | Abbvie Limited | Health | To discuss access to oncology medicines, HCV elimination and non-medical switching (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2019 | Abbvie Limited | Health | To discuss proposed changes to legislation regarding Supplementary Protection Certificates (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Abbvie Limited | Health | To discuss Ireland's medical supply chain (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2019 | Abbvie Limited | Health | To discuss Ireland's HCV elimination policy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2018 | Abbvie Limited | Health | Provided Industry briefing on delay in access to new medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2018 | Abbvie Limited | Economic Development and Industry | To present the EY-DKM report on the importance of a robust IP framework to the Pharmaceutical Industry along with the Trade Associations submission to the public consultation on the EU SPC Waiver proposal (Legislation) | 1 | On lobbying.ie |
| May–Aug 2018 | Abbvie Limited | Health | To highlight delays in access to an innovative new medicine for Chronic Lymphocytic Leukaemia for patients in Ireland that is available in other European countries (Public policy or programme) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 50 | 84.7% | |
| Economic Development and Industry | 5 | 8.5% | |
| EU Affairs | 1 | 1.7% | |
| Energy and Natural Resources | 1 | 1.7% | |
| Environment | 1 | 1.7% | |
| Taxation | 1 | 1.7% |